SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-246785
Filing Date
2022-09-19
Accepted
2022-09-19 08:10:57
Documents
15
Period of Report
2022-09-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d382643d8k.htm   iXBRL 8-K 38902
2 EX-10.1 d382643dex101.htm EX-10.1 273563
3 EX-10.2 d382643dex102.htm EX-10.2 94497
4 EX-99.1 d382643dex991.htm EX-99.1 10110
  Complete submission text file 0001193125-22-246785.txt   640075

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vtyx-20220917.xsd EX-101.SCH 2851
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtyx-20220917_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtyx-20220917_pre.xml EX-101.PRE 11704
9 EXTRACTED XBRL INSTANCE DOCUMENT d382643d8k_htm.xml XML 3471
Mailing Address 662 ENCINITAS BLVD., STE. 250 ENCINITAS CA 92024
Business Address 662 ENCINITAS BLVD., STE. 250 ENCINITAS CA 92024 (858) 945-2393
Ventyx Biosciences, Inc. (Filer) CIK: 0001851194 (see all company filings)

IRS No.: 832996852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40928 | Film No.: 221249440
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences